TechnipFMC Publishes Q3 2026 Earnings Call Transcript
Bitget2026/10/30 08:23- TechnipFMC held its Q3 2026 earnings call October 29, attended by CEO Douglas Pferdehirt and CFO Alf Melin.
- Management expects at least $14.5 billion in Subsea orders over five quarters; two to three large awards could slip into 2027.
- Subsea revenue guidance for 2027 is $10 billion-$10.4 billion, with an adjusted EBITDA margin of 22.5%-24%.
- For 2026, management raised Subsea revenue guidance to $9.6 billion-$9.8 billion; free cash flow guidance increased to $1.45 billion-$1.55 billion.
- The 2027 outlook implies Subsea incremental margins approaching 50%, excluding contributions from iEPCI 2.0.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
